Rasburicase

Summary

Rasburicase (CHEMBL1201594) is an approved enzyme (ATC M04AX01); indicated across 9 conditions including leukemia and lymphoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Enzyme
• ATC class: M04AX01 (+1 more)
• Indications: 9 conditions
• Clinical trials: 22

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201594
Name	Rasburicase
Type	Enzyme
Max phase	4
ATC	M04AX01, V03AF07

Also known as: Elitek, Fasturtec, Rasburicasa, Rasburicase, Rasuritek, SR-29142, SR29142, Urate oxidase, RASBURICASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
leukemia	4	MONDO:0005059	EFO:0000565
lymphoma	4	MONDO:0005062	EFO:0000574
gout	4	MONDO:0005393	EFO:0004274
tumor lysis syndrome	3	MONDO:0043875	EFO:1001479
Burkitt lymphoma	2	MONDO:0007243	EFO:0000309
diffuse large B-cell lymphoma	2	MONDO:0018905	EFO:0000403
anaplastic large cell lymphoma	2	MONDO:0020325	EFO:0003032

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 22.

Phase distribution

Phase	Trials
PHASE4	7
PHASE2	7
PHASE3	3
Not specified	3
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00230217	PHASE4	COMPLETED	Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
NCT00302653	PHASE4	COMPLETED	Rasburicase in Tumor Lysis Syndrome
NCT00563771	PHASE4	COMPLETED	Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome
NCT00651911	PHASE4	COMPLETED	Fasturtec TLS Treatment / Prophylysis
NCT04349306	PHASE4	COMPLETED	Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin’s Lymphoma and Acute Leukemia
NCT04745910	PHASE4	COMPLETED	Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
NCT05312268	PHASE4	UNKNOWN	Rasburicase Treatment in Chronic Gouty Arthritis
NCT00199043	PHASE3	COMPLETED	Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma
NCT00230178	PHASE3	COMPLETED	Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
NCT00607152	PHASE3	TERMINATED	Rasburicase (Fasturtec) Registration Trial
NCT00057811	PHASE2	COMPLETED	Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
NCT00290992	PHASE2	COMPLETED	Rasburicase for Hyperuricemia
NCT00360438	PHASE1/PHASE2	COMPLETED	Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS
NCT00631579	PHASE2	COMPLETED	Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma
NCT00664144	PHASE2	TERMINATED	Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin’s Lymphoma
NCT00756964	PHASE2	COMPLETED	Lowering Serum Uric Acid to Prevent Acute Kidney Injury
NCT01200485	PHASE2	COMPLETED	Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
NCT01564277	PHASE2	TERMINATED	Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
NCT00513474	PHASE1	COMPLETED	Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
NCT00186940	Not specified	COMPLETED	Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
NCT01931527	Not specified	COMPLETED	Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status
NCT03395977	Not specified	COMPLETED	Uric Acid Effects on Endothelium and Oxydative Stress

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).